Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure

The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes. The data of the latest studies (EMPEROR reduced, VERTIS CV, SOLOIST-WHF, SCORED) are p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Rossiĭskiĭ kardiologicheskiĭ zhurnal 2021-02, Vol.26 (1), p.4235
Hauptverfasser:	Kovalenko, E. V., Lozhkina, M. V., Arabidze, G. G., Kryakushkin, V. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	canagliflozin dapagliflozin empagliflozin ertugliflozin heart failure sodium-glucose co-transporter-2 inhibitor sotagliflozin type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes. The data of the latest studies (EMPEROR reduced, VERTIS CV, SOLOIST-WHF, SCORED) are presented in more detail.
ISSN:	1560-4071 2618-7620
DOI:	10.15829/1560-4071-2021-4235